ERG/EOG Study in AMD Patients Treated With Ranibizumab

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
Retina Center, Minnesota
Study ID
NCT00791427
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
55 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    0.05 ml of ranibizumab injected into the eye monthly for one year

Study Details

This is an open-label study assessing electrophysiologic testing of the retina with Electoretinogram (ERG) /Electrooculogram (EOG) tests in patients with exudative age-related macular degeneration (AMD). The standard FDA-approved treatment for wet AMD is ranibizumab (Lucentis). This study focuses on the ERG and EOG tests to evaluate retinal responses to ranibizumab treatment in AMD.

Key Dates

First listed
Nov 14, 2008
Start date
Nov 30, 2008
Status verified
May 2015
Primary completion
Sep 30, 2011
Completion
Sep 30, 2011

Study Design

Enrollment
10 participants (actual)

Arms

  • Arm: AMD Patients

Primary Outcome Measure

ERG/EOG [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Retina CenterMinneapolisMinnesota55404-

Find similar trials in Minneapolis, MN

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
The Retina Center· Minneapolis, MN

Related Studies